Atara Bio's Collaborating Investigators to Present Interim Results from Phase 1 Trial of the Autologous Version of ATA188 in ...
March 17 2017 - 12:45PM
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical
company focused on developing meaningful therapies for patients
with unmet medical needs in diseases that have seen limited
therapeutic innovation, today announced that interim Phase 1 trial
results from autologous, targeted Epstein-Barr Virus (EBV) Specific
Cytotoxic T Lymphocytes (CTL), or the autologous version of ATA188,
will be presented by its collaborating investigators at the QIMR
Berghofer Medical Research Institute and The University of
Queensland during the 69th American Academy of Neurology (AAN)
Annual Meeting. The meeting will take place in Boston,
Massachusetts from April 22-28, 2017.
Abstract Title: Symptomatic and
objective clinical improvement in progressive multiple sclerosis
patients treated with autologous Epstein–Barr virus-specific T cell
therapy: Interim results of a phase I trial
The emerging science program emphasizes ongoing neurosciences
research of an extraordinary nature, which warrants expedited
presentation. Emerging science abstracts have key aspects of the
research conducted after the original abstract submission
deadline.
About ATA188
EBV is associated with a wide range of hematologic malignancies
and solid tumors, as well as certain autoimmune conditions such as
multiple sclerosis. T-cells are a critical component of the
body's immune system and can be harnessed to counteract viral
infections, cancers, and certain autoimmune disorders. By focusing
the T-cells on specific proteins involved in the disease, the power
of the immune system can be employed to combat the condition.
ATA188 utilizes a technology in which T-cells are educated to
recognize specific antigens of EBV that are implicated in MS. In
the context of MS, ATA188 finds the EBV-infected B cells in the
central nervous system that may catalyze autoimmune response and MS
pathophysiology. The autologous version of ATA188 is currently
being studied in an ongoing Phase 1 clinical trial in patients with
primary and secondary progressive MS. Atara Bio plans to initiate a
Phase 1 trial of allogeneic ATA188 in patients with MS in the
second half of 2017.
About Atara Biotherapeutics’ Allogeneic Cellular Therapy
Platform
Atara Bio's cellular therapy platform provides healthy immune
capability to a patient and arms the immune system to precisely
target and combat disease. Cells derived from healthy donors are
manufactured in advance and stored as inventory so that a
customized unit of cells can be chosen for each patient. The cells
are ready to infuse in approximately 3 to 5 days. Once
administered, the cells home to their target, expand in-vivo to
eliminate diseased cells, and eventually recede. This versatile
platform can be directed towards a broad array of disease causing
targets and has demonstrated clinical proof of concept across both
viral and non-viral targets in conditions ranging from liquid and
solid tumors to infectious and autoimmune diseases. The Company has
pursued prospective feedback from health authorities on both
manufacturing and clinical trial design. Atara Bio’s lead product
candidate has the potential to be the first commercial allogeneic
T-cell therapy for a viral target implicated in cancer.
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. is a biopharmaceutical company
developing meaningful therapies for patients with severe and
life-threatening diseases that have been underserved by scientific
innovation, with an initial focus on allogeneic T-cell therapies
for cancer, autoimmune, and infectious disease. Atara Bio's T-cell
product candidates harness the power of the immune system to
recognize and attack cancer cells and cells infected with certain
viruses. The Company's initial clinical stage T-cell product
candidates include Epstein-Barr virus targeted Cytotoxic T-cells
(EBV-CTL), or ATA129, Cytomegalovirus targeted Cytotoxic T-cells
(CMV-CTL), or ATA230, and Wilms Tumor 1 targeted Cytotoxic T-cells
(WT1-CTL), or ATA520. These product candidates have demonstrated
the potential to have therapeutic benefit in a number of clinical
indications including hematologic malignancies, solid tumors, and
refractory viral infections. The Company is also developing a next
generation of allogeneic T-cell product candidates utilizing a
technology to selectively enhance a T-cell's ability to target
specific viral proteins implicated in disease. Initial clinical
investigations employing this approach will focus on multiple
sclerosis and other virally mediated cancers and infections.
INVESTOR & MEDIA CONTACTS:
Investors:
Steve Klass, Burns McClellan on behalf of Atara Bio
212-213-0006 x331
sklass@burnsmc.com
Media:
Justin Jackson, Burns McClellan
212-213-0006 x327
jjackson@burnsmc.com
Atara Biotherapeutics (NASDAQ:ATRA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Atara Biotherapeutics (NASDAQ:ATRA)
Historical Stock Chart
From Apr 2023 to Apr 2024